EA201170218A1 - Лечение воспалительных заболеваний бета-дефенсинами млекопитающих - Google Patents

Лечение воспалительных заболеваний бета-дефенсинами млекопитающих

Info

Publication number
EA201170218A1
EA201170218A1 EA201170218A EA201170218A EA201170218A1 EA 201170218 A1 EA201170218 A1 EA 201170218A1 EA 201170218 A EA201170218 A EA 201170218A EA 201170218 A EA201170218 A EA 201170218A EA 201170218 A1 EA201170218 A1 EA 201170218A1
Authority
EA
Eurasian Patent Office
Prior art keywords
defensins
treatment
beta
mammals
inflammatory diseases
Prior art date
Application number
EA201170218A
Other languages
English (en)
Russian (ru)
Inventor
Таня Мария Росенкилле Кьер
Томас Крусе
Пер Хольсе Мюгинн
Каролине Сидельманн Бринч
Серен Кьерульфф
Биргитте Андерсен
Original Assignee
Новозимс Эдениум Байотек А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41445843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201170218(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новозимс Эдениум Байотек А/С filed Critical Новозимс Эдениум Байотек А/С
Publication of EA201170218A1 publication Critical patent/EA201170218A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
EA201170218A 2008-07-18 2009-07-17 Лечение воспалительных заболеваний бета-дефенсинами млекопитающих EA201170218A1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08160761 2008-07-18
EP08162486 2008-08-15
EP08163614 2008-09-03
EP09160448 2009-05-15
PCT/EP2009/059251 WO2010007165A2 (en) 2008-07-18 2009-07-17 Treatment of inflammatory diseases with mammal beta defensins

Publications (1)

Publication Number Publication Date
EA201170218A1 true EA201170218A1 (ru) 2011-08-30

Family

ID=41445843

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170218A EA201170218A1 (ru) 2008-07-18 2009-07-17 Лечение воспалительных заболеваний бета-дефенсинами млекопитающих

Country Status (18)

Country Link
US (1) US20100016232A1 (enExample)
EP (1) EP2320929B1 (enExample)
JP (1) JP2011528332A (enExample)
KR (2) KR20110044863A (enExample)
CN (1) CN102159232A (enExample)
AP (1) AP2011005537A0 (enExample)
AR (1) AR072524A1 (enExample)
AU (1) AU2009272680A1 (enExample)
BR (1) BRPI0915780A2 (enExample)
CA (1) CA2730674A1 (enExample)
CL (1) CL2011000098A1 (enExample)
EA (1) EA201170218A1 (enExample)
IL (1) IL210714A0 (enExample)
MX (1) MX2011000569A (enExample)
NZ (1) NZ590466A (enExample)
TW (1) TW201004641A (enExample)
WO (1) WO2010007165A2 (enExample)
ZA (1) ZA201100462B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2750727A1 (en) * 2008-07-18 2010-01-21 Novozymes Adenium Biotech A/S Treatment of inflammatory bowel diseases with mammal beta defensins
NZ590469A (en) * 2008-07-18 2012-08-31 Novozymes Adenium Biotech As Treatment of rheumatoid arthritis with human beta defensins (1-4)
CA2796068C (en) 2010-04-15 2022-07-19 Marine Polymer Technologies, Inc. Anti-bacterial applications of poly-n-acetylglucosamine nanofibers
KR101257228B1 (ko) * 2010-06-16 2013-04-29 주식회사 나이벡 항균 또는 항염증 활성을 가지는 펩타이드 및 이를 유효성분으로 함유하는 약제학적 조성물
MX356877B (es) * 2011-04-15 2018-06-19 Marine Polymer Tech Inc Tratamiento de enfermedades con nanofibras de poli-n-acetil-glucosamina.
US9217021B2 (en) 2011-07-08 2015-12-22 Defensin Therapeutics Aps Oral treatment of inflammatory bowel disease
US20130052213A1 (en) 2011-08-19 2013-02-28 Novozymes A/S Novel immunomodulatory peptide
JP6151981B2 (ja) * 2013-06-18 2017-06-21 一般社団法人健康科学リソースセンター 関節リウマチ患者における生物学的製剤の有効性の予測方法
US11111284B2 (en) 2014-08-21 2021-09-07 The General Hospital Corporation Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing
GB201603653D0 (en) * 2016-03-02 2016-04-13 Cambridge Entpr Ltd Combination Therapy
KR102465341B1 (ko) 2016-04-29 2022-11-09 디펜신 테라퓨틱스 에이피에스 간, 담관 및 췌장 장애의 치료
AU2017376400A1 (en) * 2016-12-13 2019-06-20 Novozymes A/S Methods for treating inflammatory conditions of the lungs
KR102631542B1 (ko) * 2018-03-14 2024-02-01 서울대학교산학협력단 염증 감소능 및 줄기세포로부터 연골세포로의 분화 촉진능을 가지는 이중 기능성 펩타이드 및 이의 용도
KR102631543B1 (ko) 2018-03-14 2024-02-01 서울대학교산학협력단 세포 투과능 및 근육 재생능을 가지는 이중 기능성 펩타이드 및 이의 용도
WO2020046002A1 (ko) * 2018-08-31 2020-03-05 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
KR102244161B1 (ko) 2018-08-31 2021-04-26 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
CA3249846A1 (en) 2022-01-28 2023-08-03 Johnson & Johnson Consumer Inc Predictive Biomarkers for Atopic Dermatitis
CA3255425A1 (en) 2022-04-04 2023-10-12 Univ College Cork National Univ Of Ireland Cutaneous Therapy Regimen Window of Opportunity and Composition for Preventing or Treating Atopic Dermatitis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
US20060115480A1 (en) * 2002-12-19 2006-06-01 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
GB0514482D0 (en) * 2005-07-14 2005-08-17 Ares Trading Sa Protein
WO2007081486A2 (en) * 2005-12-15 2007-07-19 Ventria Bioscience Oral administration of defensins to treat intestinal diseases
JP5491396B2 (ja) * 2007-09-11 2014-05-14 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのデフェンシンペプチドの使用
NZ590469A (en) * 2008-07-18 2012-08-31 Novozymes Adenium Biotech As Treatment of rheumatoid arthritis with human beta defensins (1-4)
CA2750727A1 (en) * 2008-07-18 2010-01-21 Novozymes Adenium Biotech A/S Treatment of inflammatory bowel diseases with mammal beta defensins

Also Published As

Publication number Publication date
CA2730674A1 (en) 2010-01-21
AU2009272680A1 (en) 2010-01-21
EP2320929A2 (en) 2011-05-18
CL2011000098A1 (es) 2011-10-07
KR20110031962A (ko) 2011-03-29
NZ590466A (en) 2012-08-31
MX2011000569A (es) 2011-02-23
AR072524A1 (es) 2010-09-01
BRPI0915780A2 (pt) 2019-03-12
JP2011528332A (ja) 2011-11-17
CN102159232A (zh) 2011-08-17
KR20110044863A (ko) 2011-05-02
US20100016232A1 (en) 2010-01-21
WO2010007165A2 (en) 2010-01-21
AP2011005537A0 (en) 2011-02-28
ZA201100462B (en) 2013-03-27
EP2320929B1 (en) 2019-05-29
IL210714A0 (en) 2011-03-31
WO2010007165A3 (en) 2010-06-03
TW201004641A (en) 2010-02-01

Similar Documents

Publication Publication Date Title
EA201170218A1 (ru) Лечение воспалительных заболеваний бета-дефенсинами млекопитающих
GT201400057A (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
EA201270575A1 (ru) Соединения
EA201270100A1 (ru) Пиримидиноны в качестве ингибиторов pi3k
EA201300730A1 (ru) Производные индазолилтриазола
EA201100765A1 (ru) Наночастицы длительной циркуляции для замедленного высвобождения терапевтических средств
EA201290540A1 (ru) Лечение заболеваний сердца
PH12012501680A1 (en) Compositions and methods for the diagnosis and treatment of tumor
UY35470A (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
EA201071057A1 (ru) Производные азетидина и циклобутана как ингибиторы jak-киназ
PH12012501542A1 (en) Treatment of inflammatory bowel diseases with mammal beta defensis
EA201100302A1 (ru) Лечение диабета у пациентов, для которых лечение метформином является неприемлемым
EA201200977A1 (ru) Лечение синдрома ли и ли-подобного синдрома токотриенолхинонами
EA201290744A1 (ru) Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
BR112014005103A2 (pt) composições orgânicas para tratar doenças associadas com hsf1
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
NZ702334A (en) New diazaspirocycloalkane and azaspirocycloalkane
EA201291034A1 (ru) АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ B-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ
CR20110560A (es) Métodos de tratamiento para tumores sólidos
EA201101530A1 (ru) ИММУНОНАНОТЕРАПИЯ, ОБЕСПЕЧИВАЮЩАЯ Th1-СМЕЩЕННЫЙ ОТВЕТ
EA201101686A1 (ru) Новые композиции для лечения шмт и связанных с ней расстройств
CR11818A (es) Derivados de triazol utiles para el tratamiento de enfermedades
EA201201374A1 (ru) Лечение атаксии-телеангиэктазии
EA201391154A2 (ru) Способы и композиции для нацеливания на адипоциты у млекопитающих